In its second-quarter 2026 report, published in July, the company struck a markedly more confident tone. Chief executive Fredrik Dalborg said AddLife's companies were performing well across the board, with stronger margins, good growth and increased cash flow. Investors agreed: the shares jumped roughly …
The headline question is whether that pivot can carry Adicet from encouraging Phase 1 signals to a genuine registrational programme. As of 12 August 2026 the company has reported positive preliminary lupus data, held FDA interactions on a pivotal design, and guided to a …
The AIM-listed precision medicine data group posted a striking jump in annualRecurring Revenueand swung back to profit, yet Diaceutics shares have fallen sharply in recent weeks as investors weigh valuation against execution risk.
Months after a fabricated-revenue scandal forced a restatement of its accounts, SkinBioTherapeutics shares are still under pressure, with a shrinking cash pile now adding to the list of investor concerns.
ProBiotix Health reported a swing to EBITDA and net profit alongside 53%Revenuegrowth in its first-half results, yet the thinly traded AQSE stock has remained highly volatile, underscoring howIlliquidsmall-cap shares can move sharply on modest volumes even when the underlying numbers improve.
On 6 August 2026 the company reported second-quarter results and laid out a dense schedule of catalysts. Chief executive Dr Neal Walker described the first half as "a period of strong execution" that positions Aclaris "for an exciting second half of the year with …
For a clinical-stage biotech, cash is oxygen — and in mid-2026 ABIONYX Pharma (EPA:ABNX) secured a fresh supply. In late May 2026 the French company launched a fully securedCapitalincrease alongside structuredDebtfor an aggregate of up to approximately €33m, completed by late June. Management says …
The headline asks whether October's data could rewrite the story. The honest answer, as of 12 August 2026, is that the story had already partly rewritten itself: in late June, additional data and an expanded safety database prompted a powerful rebound. This article examines …
The stakes are high because Acadia has been here before: pimavanserin failed to win clearance in dementia and Alzheimer's psychosis earlier this decade, and now a new molecule carries the same ambition. On the evidence available to 12 August 2026, the headline's framing is …
The headline poses a fair question: is Abingdon approaching a profitability inflection? The evidence is encouraging but nuanced. Adjusted EBITDA profit in one half-year is not the same as sustained bottom-line profit, and the group still carries losses, thin margins and negative operating cash …